immuno-onco-popup3

Cancer Target Rationale

T-cell immunoglobulin and mucin domain-3 (TIM-3) is a negative regulatory checkpoint molecule that regulates T-cell exhaustion, dampens the antitumor immune response, and may promote tumor cell migration and invasion.1

Overview

Cobolimab is a humanized TIM-3 antagonist immunoglobulin G4 (IgG4) mAb being investigated as a monotherapy and in combination with dostarlimab and encelimab in advanced solid tumors, including melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer.2

References

1. Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276(1):97-111.
2. ClinicalTrials.gov. Accessed September 21, 2021. www.clinicaltrials.gov/